a CSIR Unit for Research and Development of Information Products (CSIR-URDIP) , Pune , India.
Expert Opin Ther Pat. 2019 Jun;29(6):463-479. doi: 10.1080/13543776.2019.1620205. Epub 2019 May 28.
Mangiferin and its derivatives possess diverse biological activities and desirable drug like properties. In continuation with the authors' previous publication, the present study reviews recently published patents in correlation with efforts of drug development using mangiferin.
Patents published after the year 2013 were analyzed for therapeutic and cosmetic applications of mangiferin, its salts, derivatives, and preparations. Patent information pertaining to improving solubility and bioavailability of mangiferin and related bioactives has also been presented. Methods of extraction of mangiferin and poly herbal preparations have not been included. Biological testing data has been put forth to understand the clinical trial status of products comprising mangiferin and/or its derivatives.
Mangiferin has been highlighted as a multitarget bioactive with therapeutic potential. Research efforts in the recent years have contributed to development of new mangiferin derivatives as well as mangiferin formulations with enhanced solubility and bioavailability. Improvements in drug delivery systems for mangiferin might contribute to designing clinical trials to validate its therapeutic potential in humans. Majority of the recent patents have been filed by Chinese inventors claiming second medical use of mangiferin or its related compounds. However, a number of these patents remain in the prosecution stage.
山竹堿及其衍生物具有多种生物活性和理想的药物特性。本研究延续了作者之前的出版物，综述了近年来与山竹堿药物开发相关的已发表专利。
分析了 2013 年以后发表的专利，涉及山竹堿、其盐、衍生物和制剂的治疗和美容应用。还介绍了提高山竹堿和相关生物活性物质溶解度和生物利用度的专利信息。未包括山竹堿的提取方法和多草药制剂。为了了解包含山竹堿和/或其衍生物的产品的临床试验状况，提出了生物测试数据。
山竹堿已被强调为具有治疗潜力的多靶点生物活性物质。近年来的研究工作促进了新型山竹堿衍生物的开发，以及提高山竹堿溶解度和生物利用度的制剂的开发。改善山竹堿的药物传递系统可能有助于设计临床试验，以验证其在人类中的治疗潜力。最近的大多数专利都是由中国发明人提交的，他们声称山竹堿或其相关化合物具有第二医疗用途。然而，其中许多专利仍处于起诉阶段。
